We accounted for the fact that approximately 50% of melanomas of all clinical types present an activating mutation in the BRAF oncogene, while about 20% of the cases show an activating mutation in NRAS, leading to the activation of the MAPK signaling pathway (cellular proliferation and survival depend on such pathway). Here, BRAF is linked to melanoma.